Tag:
Vidaza
Latest Headlines
Latest Headlines
EMA pulls cancer meds made by troubled CMO
More bad news for customers of the contract manufacturer Ben Venue Laboratories : European authorities are recalling three cancer drugs made by the Boehringer Ingelheim unit and putting restrictions
Celgene pricing convinces NICE to OK Vidaza
Celgene has struck a NICE deal. After an initial rebuff, the U.S.-based drugmaker's blood cancer drug Vidaza won a recommendation from the the National Institute for Health and Clinical Excellence to
Celgene goes global with $2.9B Pharmion buyout
Celgene took a big stride toward its goal of becoming a global marketer of blood cancer therapies with the news over the weekend that it is buying Pharmion for $2.9 billion. That buyout amount is 11
ALSO NOTED: Neuren buys Hamilton Pharma; Merck pulls out of MethyGene collaboration; Par licenses Zensana rights; and much more
> New Zealand's Neuren is acquiring Washington D.C.-based Hamilton Pharmaceuticals for $4.4 million in a deal that delivers the license for a drug called Motiva, a late-stage preclinical compound
